Loading...
Market
Story
Study of 9.2 Million Links Hallucinogen Use to 21-Fold Increased Schizophrenia Risk, Potential for Psilocybin Therapy for 5.6 Million Americans
Nov 13, 2024, 11:54 PM
A recent study conducted in Ontario, Canada, has found a significant correlation between hallucinogen use and an increased risk of developing schizophrenia. The research analyzed data from over 9.2 million individuals and revealed that those who visited emergency departments (EDs) due to hallucinogen use faced a 21-fold higher risk of developing schizophrenia spectrum disorders (SSD) compared to the general population and individuals who sought treatment for other substances. Additionally, psilocybin-assisted therapy has been identified as potentially beneficial for up to 5.6 million Americans suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD), highlighting the growing interest in psychedelics for mental health treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
High-dose psilocybin more effective • 25%
SSRIs more effective • 25%
Equally effective • 25%
No significant difference • 25%
Significant positive effects • 25%
Moderate positive effects • 25%
No significant effects • 25%
Negative effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Roche • 25%
Yes • 50%
No • 50%
Depression • 25%
Anxiety • 25%
PTSD • 25%
Addiction • 25%
Yes • 50%
No • 50%
Peganum harmala • 25%
Nymphaea nouchali var. caerulea • 25%
Cleome genus • 25%
Other • 25%